The Hindu Business Line : Ranbaxy launches new drug for urological disorder

RANBAXY Laboratories Ltd today announced the launch of its benign prostatic hyperplasia (BPH) formulation, branded Flotral (Alfuzosin). It is being launched for the first time in the Indian market.

This prescription medicine provides effective relief from signs and symptoms of BPH, a urological disorder, caused due to the enlargement of the prostate gland and commonly afflicts the ageing male population.

Flotral, is a once-a-day medication, developed using the Novel Drug Delivery System (NDDS) technology platform, resulting in better patient compliance.

Mr Sanjeev I. Dani, Regional Director - India, said in a statement, "The launch of Flotral further expands Ranbaxy's key strategic product portfolio and establishes the company's commitment to build its urology franchise through its competitive edge technology of NDDS."

Meanwhile, the pharmaceutical company is planning to restructure its business by exiting from its non-core segments such as animal healthcare, diagnostics and fine chemicals.

These account for close to Rs 125 crore of the company's turnover.

When contacted Ranbaxy officials "refused to comment on market rumours".

According to an analyst tracking the company, "The decision to hive off the non-core business will enable the company to focus on its core pharmaceuticals business. Except for the Fine Chemicals business, the company may be of the view that there are no synergies with the other business, though these segments may demand dedicated resources."

More Stories on : Announcements | New Products & Services | Health | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Mukesh clarifies on `ownership issues'

Ranbaxy launches new drug for urological disorder

Deccan Chronicle plans launch in TN by Feb `05

ABB to invest $100 m in India

Reliance keen on bringing gas to Bengal from K-G find

BHEL bags Rs 26-cr orders

ICAI disclosure norms for court-ordered accounts

Ford India sales income up 29 pc; net loss pared

To fund capacity expansion — Bajaj Hind mulls Rs 100-cr equity infusion

Talks on Bajarang Jute mill reopening

Deccan Gold signs exploration pact with De Beers

DS Group plans jt venture with Lotte for confectionery biz

Motherson Sumi to set up second venture with Woco

Eicher eyes Rs 2,000-cr turnover this fiscal

MPI to invest Rs 10 cr to double capacity

The meeting that never was

Rupee options a hit among corporates